title: Antibody-based concepts for multipurpose prevention technologies.
abstract: Because of the versatility and specificity of monoclonal antibodies, they are candidates for multipurpose prevention technologies when formulated as topical (gels, films, rings) or injectable drugs and as vaccines. This review focuses on antibody-based proof of concept studies for the human immunodeficiency virus, herpes simplex virus and sperm. Opportunities and challenges in antibody evasion/resistance, manufacturing, regulatory, and pharmacoeconomics are discussed. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.
authors.affiliation: Mapp Biopharmaceutical, Inc., San Diego, CA, USA. Electronic address: Kevin.whaley@mappbio.com.
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Whaley
authors.forename: Larry
authors.initials: L
authors.lastname: Zeitlin
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006561:Herpes Simplex / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D018139:Simplexvirus / Q000187:drug effects* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents
keywords: Herpes simplex virus; Human immunodeficiency virus; Multi-antibody; Multipurpose prevention technologies; Sperm